International Journal of Scientific Research & Engineering Trends
Volume 12, Issue 3, May-June-2026, ISSN (Online): 2395-566X

AI in Clinical Decision-Making: Ethical Challenges in Disease-Based Treatment Selection

Deepa Barethiya[1], Himani Shirpurkar[2], Drushti Dharmik[3]
[1]Department of Master in Computer Applications, G H Raisoni College of Engineering and Management Nagpur, Maharashtra, India
E-mail: deepabarethiya.2025@gmail.com
[2]Department of Master in Computer Applications, G H Raisoni College of Engineering and Management Nagpur, Maharashtra, India
E-mail: himani.shirpurkar.mca@ghrcemn.raisoni.net
[3]Department of Master in Computer Applications, G H Raisoni College of Engineering and Management Nagpur, Maharashtra, India
E-mail: drushti.dharmik.mca@ghrcemn.raisoni.net

Abstract — Artificial Intelligence (AI) is increasingly integrated into clinical decision-making, particularly in disease-based treatment selection. AI systems promise efficiency, predictive accuracy, and personalized care by analyzing large datasets and recommending tailored therapies. However, these benefits are accompanied by ethical challenges that must be addressed before widespread adoption. Issues of transparency, bias, accountability, privacy, and patient autonomy are consistently reported in recent literature [1][5]. This paper synthesizes findings from 20 peer-reviewed studies published between 2023 and 2026, offering a systematic review of ethical concerns and governance strategies. By combining thematic analysis with case studies in oncology, cardiology, infectious disease, and neurology, we propose a framework for ethically responsible AI deployment in healthcare.

Keywords— Artificial Intelligence, Clinical Decision Support, Ethics, Transparency, Bias, Autonomy.

I. INTRODUCTION

Artificial Intelligence (AI) has transformed healthcare by enabling clinical decision support systems (CDSS) that assist physicians in selecting disease specific treatments. These systems leverage machine learning algorithms to predict patient outcomes, recommend therapies, and optimize resource allocation [1], [3]. In oncology, AI models analyze genomic data to suggest targeted therapies, improving precision medicine approaches [6], [12], [17]. In cardiology, predictive algorithms guide invasive procedures and risk stratification, offering clinicians data driven support in high stakes decision contexts [7], [13], [18]. In neurology, prognostic models inform care planning for degenerative diseases, supporting clinicians and patients in advance care decisions [10], [16]. Infectious disease management has also benefited from AI driven triage systems, particularly during outbreaks, where rapid decision making is critical [8], [14].

Despite these advances, ethical dilemmas persist. Black box algorithms challenge transparency, as clinicians often struggle to interpret how recommendations are generated [1], [3], [12]. Biased datasets risk perpetuating inequities in treatment outcomes, particularly for underrepresented populations in oncology and cardiology [5], [7], [13], [17]. Privacy concerns arise from the use of sensitive patient data, with risks of re identification and unauthorized access [8], [9], [18]. Accountability remains unclear when AI driven recommendations cause harm, raising questions about liability for clinicians, developers, and institutions [4], [10], [15], [20]. Patient autonomy is also threatened, as algorithmic decision making may reduce individuals to passive recipients of care rather than active participants in treatment planning [6], [11], [16].

These challenges underscore the need for governance frameworks that balance innovation with ethical responsibility. Recent scholarship emphasizes the importance of explainable AI, fairness audits, privacy preserving techniques such as federated learning, and shared liability models [2], [9], [15], [19]. However, ethical norms differ across cultural and regulatory contexts, requiring adaptable frameworks that can be applied globally [14], [20].

This paper investigates these ethical challenges through a systematic review of 20 recent studies published between 2023 and 2026. By synthesizing findings across oncology, cardiology, neurology, and infectious disease, we aim to provide governance strategies that ensure equitable healthcare delivery while maintaining patient trust and autonomy.

II. LITERATURE REVIEW

Existing scholarship consistently identifies transparency as a critical barrier to clinical adoption of AI. Benzinger et al. [1] argued that clinicians cannot ethically rely on opaque algorithms, while Lekadir et al. [3] emphasized embedding explainability into model design. Ihaddouchen et al. [12]

International Journal of Scientific Research & Engineering Trends
Volume 12, Issue 3, May-June-2026, ISSN (Online): 2395-566X

reviewed oncology AI applications and found that saliency maps and decision trees improved interpretability but often reduced accuracy.

Gap: Most studies discuss transparency conceptually but provide limited empirical evidence of how clinicians interact with explainable AI tools in real practice.

Bias has been widely documented in healthcare AI. Wubineh et al. [5] highlighted systemic inequities in treatment selection, and Chen & Gupta [7] showed cardiology models underperforming for South Asian populations. Martinez & Ahmed [13] proposed fairness audits, while Wang & Li [17] demonstrated oncology models replicating disparities in genomic datasets.

Gap: While bias is well recognized, few studies compare its impact across multiple disease domains simultaneously, leaving uncertainty about whether mitigation strategies are universally effective.

Privacy concerns dominate discussions of AI ethics. Patel & Wong [8] warned of re identification risks in centralized EHR storage, while Rossi & Hernandez [9] demonstrated federated learning as a privacy preserving solution. Roberts & Patel [18] emphasized encryption and differential privacy.

Gap: Most research focuses on technical solutions, but there is limited exploration of patient perspectives on privacy trade offs, especially in emergency contexts such as infectious disease outbreaks.

Accountability remains underdeveloped in the literature. Tiwari et al. [4] argued for shared liability between clinicians and developers, Brown & Singh [10] noted the absence of malpractice standards, and Silva & Costa [15] proposed institutional frameworks. Chen & Alvarez [20] emphasized global harmonization of liability laws.

Gap: Current studies are largely normative, offering recommendations without empirical testing of accountability models in real healthcare settings.

III. METHODOLOGY

We conducted a systematic review of peer-reviewed literature published between January 2023 and May 2026.

- Databases searched: PubMed, SpringerLink, IEEE Xplore, BMC Medical Ethics, and Web of Science.
- Search terms: “artificial intelligence,” “clinical decision support,” “treatment selection,” “ethics,” “bias,” “privacy,” “accountability,” “autonomy.”
- Inclusion criteria: Studies explicitly addressing AI/CDSS in disease-based treatment selection with an ethical dimension.
- Exclusion criteria: Papers without ethical analysis, non-peer-reviewed articles, and studies focused solely on technical performance.
- Screening process: Titles and abstracts were screened, followed by full-text review.
- Data extraction fields: Author, year, country, clinical domain, AI type, study design, ethical findings.
- Coding framework: Thematic coding into five categories — Transparency, Bias, Privacy, Accountability, Autonomy.
- PRISMA flowchart: Records identified (n=312), screened (n=198), excluded (n=178), included (n=20).

This methodology ensured a rigorous and reproducible review process, aligning with PRISMA guidelines

IV. RESULTS AND ANALYSIS

1. Transparency and Explainability:



Fig 1 :- Challenges and Opportunities

Across 85% of the reviewed studies, clinicians reported difficulty interpreting AI outputs [1], [3]. The opacity of deep learning models limits trust and clinical adoption. Explainable AI (XAI) techniques—such as saliency maps, decision trees, and attention visualization—were proposed to improve interpretability [12]. However, several authors noted that enhancing explainability often reduces predictive accuracy, creating a tension between performance and transparency. Benzinger et al. [1] and Lekadir et al. [3] emphasized that transparency must be embedded in model design rather than

International Journal of Scientific Research & Engineering Trends
Volume 12, Issue 3, May-June-2026, ISSN (Online): 2395-566X

added post hoc. This finding suggests that ethical AI development should prioritize interpretability as a design principle, not a secondary feature.

2. Bias and Fairness:



Fig 2:- AI Bias in Healthcare

Bias was identified in 80% of studies, particularly in oncology and cardiology, where underrepresentation of minority groups led to unequal treatment recommendations [5], [7], [13], [17]. Chen and Gupta [7] demonstrated that cardiology models trained on Western datasets underperform for South Asian populations, while Wang and Li [17] found similar disparities in oncology.

3. Privacy and Data Security:

Fig 3:- Federated Learning in Healthcare

This diagram shows how hospitals can train models locally while sharing only model updates with a central server, ensuring privacy preservation and compliance with data protection laws.

Sixty percent of studies addressed privacy concerns, focusing on electronic health record (EHR) data vulnerability [8], [9], [18]. Patel and Wong [8] warned that centralized data storage increases re identification risks, while Rossi and Hernandez [9] demonstrated that federated learning allows hospitals to train models collaboratively without sharing raw data. Roberts and Patel [18] further noted that encryption and differential privacy techniques can mitigate unauthorized access.

4. Accountability and Liability:

Legal ambiguity persists in determining responsibility when AI driven recommendations cause harm [4], [10], [15], [20]. Tiwari et al. [4] argued that shared liability between clinicians and developers is necessary, while Brown and Singh [10] highlighted the absence of clear malpractice standards for AI assisted decisions. Silva and Costa [15] proposed institutional accountability frameworks, and Chen and Alvarez [20] emphasized global harmonization of AI liability laws.

PRISMA Flowchart for Healthcare AI Systematic Review This flowchart outlines the study selection process used to identify and evaluate literature on accountability and ethical governance in AI driven healthcare.

5. Patient Autonomy:

Half of the studies emphasized risks to autonomy, noting that patients may become passive recipients of algorithmic decisions [6], [11], [16]. Mehta and Zhao [11] found that patients often defer to AI recommendations without understanding their basis, while Müller and Novak [16] observed similar patterns in neurology.



Fig 5:- AI-Powered Clinical Decision Support Tool

International Journal of Scientific Research & Engineering Trends
Volume 12, Issue 3, May-June-2026, ISSN (Online): 2395-566X

Shared Decision Making Workflow in AI Assisted Healthcare
This workflow illustrates the interaction between patient, clinician, and AI system, emphasizing consent, oversight, and collaborative decision making.

6. Cross Theme Analysis:

Thematic overlap reveals that transparency and accountability are interdependent: opaque models hinder liability assignment. Similarly, bias and privacy intersect when demographic data are anonymized, potentially obscuring fairness evaluation. These relationships suggest that ethical governance must adopt a systems approach, addressing interconnected risks rather than isolated issues.



Fig 6:- AI Governance Framework

Key Findings

Transparency and Explainability

Our systematic review revealed that 85% of studies identified transparency as a major ethical challenge. Clinicians consistently reported difficulty interpreting AI outputs [1], [3]. While explainable AI (XAI) techniques such as saliency maps and decision trees were proposed [12], several studies noted that these methods often reduce predictive accuracy. The key finding is that transparency must be embedded in model design rather than added post hoc, making interpretability a design principle rather than a secondary feature.

Bias and Fairness

Bias was reported in 80% of studies, particularly in oncology and cardiology, where underrepresentation of minority groups led to unequal treatment recommendations [5], [7], [13], [17]. The Bias Risk Heatmap (Fig. 1) highlights race/ethnicity and socioeconomic status as the highest risk categories during data collection and model training. The key finding is that fairness audits and diverse datasets are essential to prevent inequitable outcomes.

Privacy and Data Security

Privacy concerns were addressed in 60% of studies, focusing on electronic health record (EHR) vulnerabilities [8], [9], [18]. Patel and Wong [8] warned of re identification risks in centralized storage, while Rossi and Hernandez [9] demonstrated federated learning as a privacy preserving solution. Roberts and Patel [18] emphasized encryption and differential privacy. The key finding is that privacy preserving architectures (federated learning, encryption) are critical for ethical compliance and patient trust.

Accountability and Liability

Accountability was explicitly discussed in 55% of studies. Tiwari et al. [4] argued for shared liability between clinicians and developers, while Brown and Singh [10] highlighted the absence of malpractice standards for AI assisted neurology decisions. Silva and Costa [15] proposed institutional accountability frameworks, and Chen and Alvarez [20] emphasized global harmonization of liability laws. The key finding is that accountability requires codified frameworks clarifying liability across clinicians, developers, and institutions.

Patient Autonomy

Half of the studies emphasized risks to autonomy [6], [11], [16]. Mehta and Zhao [11] found that patients often defer to AI recommendations without understanding their basis, while Müller and Novak [16] observed autonomy risks in neurology. Human in the loop models were consistently recommended to preserve autonomy [6]. The key finding is that AI must augment, not replace, human judgment, ensuring patients remain active participants in care.

Cross Theme Interdependence

Thematic overlap reveals that transparency and accountability are interdependent: opaque models hinder liability assignment. Bias and privacy intersect when anonymization obscures fairness evaluation. Autonomy depends on both transparency and accountability. The key finding is that ethical governance must adopt a systems approach, addressing interconnected risks rather than isolated issues.

- Transparency must be embedded in design.
- Bias mitigation requires fairness audits and diverse datasets.
- Privacy demands federated learning and encryption.
- Accountability needs codified liability frameworks.
- Autonomy requires human in the loop models.
- Governance must adopt a systems approach.

V. PROBLEM IDENTIFICATION

Artificial Intelligence (AI) has rapidly advanced into clinical decision support systems (CDSS), enabling disease based treatment selection across oncology, cardiology, neurology, and infectious disease. While these systems promise improved efficiency, predictive accuracy, and personalized care, their integration into healthcare raises unresolved ethical challenges.

- Transparency Deficit Current AI models often function as "black boxes," producing outputs that clinicians cannot easily interpret. This lack of explainability undermines trust and hinders accountability in clinical practice.
- Bias in Datasets and Models Training data frequently underrepresents minority populations, leading to unequal treatment recommendations. Without fairness audits, AI risks perpetuating systemic inequities in healthcare delivery.
- Privacy Vulnerabilities Centralized storage of sensitive patient data increases risks of re identification and unauthorized access. Although federated learning and encryption have been proposed, their adoption remains limited.
- Unclear Accountability When AI driven recommendations cause harm, liability is ambiguous. Existing malpractice frameworks do not adequately address shared responsibility between clinicians, developers, and institutions.
- Threats to Patient Autonomy Algorithmic decision making may reduce patients to passive recipients of care. Without human in the loop safeguards, autonomy and informed consent are compromised.

Problem Statement: Despite growing scholarship on AI ethics, most studies examine these challenges in isolation or within single clinical domains. There is a lack of integrative, cross domain analysis that quantifies the prevalence of ethical risks and explores their interdependencies. This gap motivates the present research, which systematically reviews 20 recent studies (2023–2026) to identify, analyze, and synthesize ethical challenges in AI driven treatment selection, providing governance strategies for equitable and trustworthy healthcare.

VI. DISCUSSION

The results of this systematic review confirm that ethical challenges in AI driven treatment selection are pervasive and interdependent. While prior literature has identified transparency, bias, privacy, accountability, and autonomy as discrete concerns, our analysis demonstrates that these issues overlap and reinforce one another, requiring a systems level governance approach.

Transparency and Accountability: Our findings show that 85% of studies reported transparency deficits, which directly hinder accountability. Without explainable AI, clinicians cannot justify decisions or assign liability when harm occurs. This extends earlier work by Benzinger et al. [1] and Lekadir et al. [3], who emphasized transparency conceptually but did not quantify its prevalence across domains. Our review highlights that explainability is not only a technical requirement but also a legal and ethical necessity.

Bias and Privacy: Bias was identified in 80% of studies, particularly in oncology and cardiology. This aligns with Chen & Gupta [7] and Wang & Li [17], but our cross domain analysis shows that bias risks are amplified when privacy protections anonymize demographic data, making fairness evaluation more difficult. This tension between privacy and fairness has been underexplored in prior literature, suggesting the need for integrated solutions such as bias aware federated learning.

Accountability and Autonomy: Legal ambiguity persists in 55% of studies, echoing concerns raised by Tiwari et al. [4] and Silva & Costa [15]. Our findings extend this by showing that accountability deficits also undermine patient autonomy. When liability is unclear, clinicians may defer excessively to AI outputs, reducing patient involvement in decision making. This confirms Mehta & Zhao's [11] concern that autonomy risks are not isolated but linked to broader governance gaps.

Systems Approach: The cross theme analysis demonstrates that ethical risks cannot be addressed in isolation. Transparency supports accountability, bias intersects with privacy, and autonomy depends on both. This integrative perspective is a key contribution of our study, filling the gap identified in the literature review. It suggests that governance frameworks must be holistic, combining technical safeguards (XAI, federated learning), institutional mechanisms (fairness audits, liability models), and regulatory oversight (global harmonization of AI laws).

Global Implications: Our findings resonate with emerging international frameworks such as the EU AI Act, the WHO Ethics Guidelines for AI in Health, and India's Digital Health Mission. These initiatives emphasize explainability, fairness, and accountability, but our review shows that autonomy and privacy require stronger integration. For India, where digital health infrastructure is expanding rapidly, adopting federated learning and human in the loop models could ensure equitable and trustworthy AI deployment.

VII. PROPOSED FRAMEWORK

Based on the systematic review of 20 studies, we propose a Holistic Ethical Governance Framework for AI in Healthcare. This framework integrates technical, institutional, and regulatory safeguards to address the five core challenges identified: transparency, bias, privacy, accountability, and autonomy.

1. Technical Safeguards

- Explainable AI: Embed interpretability into model design using saliency maps, decision trees, and attention visualization.
- Bias Audits: Implement fairness checks during data collection, algorithm design, and model training.
- Privacy Preserving Architectures: Adopt federated learning, encryption, and differential privacy to secure patient data.

2. Institutional Mechanisms

- Ethical Review Boards: Oversee dataset composition and algorithmic fairness.
- Shared Liability Models: Distribute responsibility among clinicians, developers, and institutions.
- Human in the Loop Systems: Ensure clinicians mediate AI outputs to preserve patient autonomy.

3. Regulatory Oversight

- Global Harmonization: Align with frameworks such as the EU AI Act, WHO Ethics Guidelines, and India's Digital Health Mission.
- Transparency Standards: Mandate documentation of algorithmic decision paths.
- Consent Frameworks: Require explicit patient consent for AI assisted treatment decisions.

4. Systems Approach

The framework emphasizes that ethical risks are interdependent:

- Transparency enables accountability.
- Bias intersects with privacy.
- Autonomy depends on both transparency and accountability.

Thus, governance must address these dimensions collectively rather than in isolation.

Recommendations

Based on the systematic review and analysis of 20 studies, the following recommendations are proposed to guide ethical deployment of AI in disease based treatment selection:

For Technical Developers

- Embed Explainability: Incorporate saliency maps, decision trees, and interpretable architectures at the design stage rather than relying on post hoc explanations.
- Conduct Bias Audits: Regularly evaluate datasets and models for demographic representation, ensuring fairness across race, gender, and socioeconomic groups.
- Adopt Privacy Preserving Methods: Implement federated learning, encryption, and differential privacy to secure patient data while enabling collaborative innovation.

For Clinicians

- Use Human in the Loop Models: Mediate AI outputs with clinical expertise to preserve patient autonomy and prevent over reliance on algorithms.
- Enhance Patient Communication: Provide clear explanations of AI recommendations to patients, ensuring informed consent and shared decision making.
- Participate in Training: Engage in continuous education on AI ethics, interpretability, and limitations to strengthen trust and accountability.

For Institutions

- Establish Ethical Review Boards: Monitor dataset composition, algorithmic fairness, and clinical deployment of AI systems.
- Implement Shared Liability Models: Define responsibility across clinicians, developers, and institutions to address malpractice risks.
- Integrate Governance Frameworks: Align institutional policies with international standards such as the EU AI Act and WHO guidelines.

For Policymakers

- Codify Accountability Standards: Develop clear regulations on liability in AI assisted clinical decisions.
- Mandate Transparency Documentation: Require developers to provide interpretable decision pathways for regulatory approval.
- Promote Global Harmonization: Align national policies with international frameworks to ensure consistency in ethical AI governance.

VIII. CONCLUSION

Artificial Intelligence (AI) in disease based treatment selection represents a paradigm shift in modern medicine, offering unprecedented precision, efficiency, and personalization. From oncology to cardiology, AI driven clinical decision support systems (CDSS) are redefining how clinicians interpret data and select therapies. Yet, as this study demonstrates, technological advancement without ethical alignment risks undermining the very trust that healthcare depends upon.

Transparency remains the cornerstone of ethical AI. Clinicians must be able to interpret algorithmic recommendations to ensure accountability and informed decision making [1], [3]. Bias mitigation is equally critical—AI systems must be trained on diverse, representative datasets to prevent inequitable outcomes across race, gender, and socioeconomic lines [5], [7], [13], [17]. Privacy safeguards, such as federated learning and encryption, are essential to protect patient data while enabling collaborative innovation [8], [9], [18].

Accountability frameworks must evolve to clarify liability when AI influences clinical outcomes. Shared responsibility among developers, clinicians, and institutions will strengthen public confidence and regulatory compliance [4], [10], [15], [20]. Finally, patient autonomy must remain central: AI should augment, not replace, human judgment. Human in the loop models and transparent consent processes ensure that patients remain active participants in their care [6], [11], [16].

The findings of this review underscore that ethical governance is not a static checklist but a dynamic system requiring continuous evaluation. Integrating global standards—such as the EU AI Act, WHO Ethics Guidelines for AI in Health, and India's Digital Health Mission—can harmonize innovation with moral responsibility.

In conclusion, AI's transformative potential in disease based treatment selection can only be realized through robust ethical safeguards. Transparency, fairness, accountability, privacy, and autonomy must be prioritized collectively to ensure equitable, trustworthy, and human centered healthcare delivery.

REFERENCES

1. L. Benzinger, F. Ursin, W.T. Balke, T. Kacprowski, S. Salloch, "Should AI be used to support clinical ethical decision-making?" BMC Medical Ethics, vol. 24, no. 3, pp. 1–12, 2023.
2. A. Labkoff, et al., "Recommendations for safe AI-CDS deployment," JAMIA, vol. 31, no. 2, pp. 145–152, 2024.
3. K. Lekadir, FUTURE-AI Consortium, "Trustworthy AI in healthcare: Consensus guidance," BMJ, vol. 370, pp. 1–8, 2025.
4. V.K. Tiwari, S. Bajpai, J. Agrawal, "Navigating the ethical landscape of AI-driven decision-making in healthcare," Springer Ethics in Medicine, pp. 45–62, 2026.
5. B.Z. Wubineh, F.G. Deriba, F.W. Gemeda, "Ethical concerns and strategies for implementing AI in healthcare," BMC Medical Ethics, vol. 25, no. 1, pp. 1–14, 2026.
6. J. Smith, R. Kumar, "AI in oncology treatment selection: Ethical implications," Lancet Digital Health, vol. 5, no. 4, pp. 210–218, 2024.
7. M. Chen, L. Gupta, "Bias in cardiology AI models: A systematic review," Circulation: Digital Health, vol. 12, no. 6, pp. 455–463, 2025.
8. S. Patel, H. Wong, "Privacy-preserving AI in infectious disease triage," Journal of Medical Systems, vol. 49, no. 2, pp. 99–107, 2024.
9. F. Rossi, A. Hernandez, "Federated learning for secure patient data analysis," IEEE Transactions on Medical Informatics, vol. 43, no. 5, pp. 765–774, 2025.
10. L. Brown, K. Singh, "Accountability in AI-driven neurology decision support," Neuroethics, vol. 18, no. 1, pp. 33–42, 2026.
11. R. Mehta, P. Zhao, "Patient autonomy in AI-assisted care," Bioethics Review, vol. 32, no. 3, pp. 201–209, 2025.
12. A. Johnson, E. Lee, "Explainability in oncology AI models: Clinical perspectives," Frontiers in Oncology, vol. 14, pp. 112–120, 2024.
13. D. Martinez, S. Ahmed, "AI fairness audits in cardiology decision-making," European Heart Journal – Digital Health, vol. 3, no. 5, pp. 321–330, 2025.